GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Short Percentage of Float

MDXXF (Pharmala Biotech Holdings) Short Percentage of Float


View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Pharmala Biotech Holdings's Short Percentage of Float

For the Biotechnology subindustry, Pharmala Biotech Holdings's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Short Percentage of Float falls into.


Pharmala Biotech Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Short Percentage of Float
Comparable Companies
XCNQ:ASEP XCNQ:PHRM XCNQ:COOL TSXV:QPT XCNQ:TELI TSX:AEZS XCNQ:BLAB NEOE:BMND TSXV:NRX TSXV:KNE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
MDMA:Canada
Address
82 Richmond Street East, Toranto, ON, CAN, M5C 1P1
Website
https://www.pharmala.ca
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.